Artiva Biotherapeutics, Inc. Common Stock (ARTV) 10-Q29 Aug 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2024	Aug. 15, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-42179
Entity Registrant Name	Artiva Biotherapeutics, Inc.
Entity Central Index Key	0001817241
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-3614316
Entity Address, Address Line One	5505 Morehouse Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	267-4467
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ARTV
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,287,144

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 34,248	$ 53,504
Short-term investments	12,308	23,467
Accounts receivable (including related party amounts of $569 and $569, respectively)	569	1,034
Other receivables (including related party amounts of $700 and $607, respectively)	892	724
Prepaid expenses and other current assets	1,732	1,092
Total current assets	49,749	79,821
Restricted cash	258	258
Property and equipment, net	7,315	8,096
Operating lease right-of-use assets	15,129	16,547
Financing lease right-of-use asset	291
Deferred offering costs	2,840	0
Other long-term assets	330	392
Total assets	75,912	105,114
Current liabilities:
Accounts payable (including related party amounts of $223 and $199, respectively)	823	614
Accrued expenses (including related party amounts of $859 and $2,161, respectively)	6,214	8,017
Current portion of operating lease liabilities	3,674	3,596
Current portion of financing lease liability	116
Total current liabilities	10,827	12,227
Operating lease liabilities, net of current portion	11,869	13,316
Financing lease liability, net of current portion	106
Simple agreements for future equity ("SAFEs") (including related party amounts of $22,427 and $20,315, respectively)	27,720	25,100
Other non-current liabilities	74	73
Total liabilities	50,596	50,716
Commitments and contingencies (Note 11)
Stockholders' deficit:
Common stock, $0.0001 par value; 40,248,588 and 38,998,588 shares authorized at June 30, 2024 and December 31, 2023, respectively; 814,202 and 809,758 shares issued and outstanding at June 30, 2024 and December 31, 2023
Additional paid-in capital	21,899	18,988
Accumulated other comprehensive income	121	308
Accumulated deficit	(213,117)	(181,311)
Total stockholders' deficit	(191,097)	(162,015)
Total liabilities, convertible preferred stock and stockholders' deficit	75,912	105,114
Series A convertible preferred stock [Member]
Current liabilities:
Convertible preferred stock	96,767	96,767
Series B convertible preferred stock [Member]
Current liabilities:
Convertible preferred stock	$ 119,646	$ 119,646

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounts receivable	$ 569	$ 1,034
Other receivables	892	724
Accounts payable	823	614
Accrued expenses	6,214	8,017
Simple agreements for future equity	27,720	25,100
Related party [Member]
Accounts receivable	569	569
Other receivables	700	607
Accounts payable	223	199
Accrued expenses	859	2,161
Simple agreements for future equity	$ 22,427	$ 20,315
Common stock [Member]
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Common stock shares authorized	40,248,588	38,998,588
Common stock shares issued	814,202	809,758
Common stock shares outstanding	814,202	809,758
Series A convertible preferred stock [Member]
Temporary equity par or stated value per share	$ 0.0001	$ 0.0001
Temporary equity shares authorized	16,110,463	16,110,463
Temporary equity shares issued	3,673,148	3,673,148
Temporary equity shares outstanding	3,673,148	3,673,148
Temporary equity liquidation preference	$ 80,552	$ 80,552
Series B convertible preferred stock [Member]
Temporary equity par or stated value per share	$ 0.0001	$ 0.0001
Temporary equity shares authorized	10,909,091	10,909,091
Temporary equity shares issued	2,487,237	2,487,237
Temporary equity shares outstanding	2,487,237	2,487,237
Temporary equity liquidation preference	$ 120,000	$ 120,000

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Collaboration revenue		$ 3,497		$ 4,487
License and development support revenue (including related party amounts of $0, $0, $251 and $0, respectively)			$ 251
Total revenue		3,497	251	4,487
Operating Expenses [Abstract]
Research and development (including related party amounts of $1,172, $894, $1,459 and $1,810, respectively)	$ 12,333	11,262	23,488	26,033
General and administrative	3,857	4,059	7,444	7,965
Total operating expenses	16,190	15,321	30,932	33,998
Loss from operations	(16,190)	(11,824)	(30,681)	(29,511)
Other income (expense), net:
Interest income	676	509	1,326	1,533
Change in fair value of SAFEs (including related party amounts of $1,895, $0, $2,112 and $0, respectively)	(2,352)		(2,620)
Other income (expense), net	23	31	169	(23)
Total other income (expense), net	(1,653)	540	(1,125)	1,510
Net loss	$ (17,843)	$ (11,284)	$ (31,806)	$ (28,001)
Net loss per share, basic	$ (22)	$ (14.09)	$ (39.24)	$ (35.12)
Net loss per share, diluted	$ (22)	$ (14.09)	$ (39.24)	$ (35.12)
Weighted-average common shares outstanding, basic	811,210	800,889	810,484	797,403
Weighted-average common shares outstanding, diluted	811,210	800,889	810,484	797,403
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments	$ (86)	$ 127	$ (187)	$ 127
Comprehensive loss	$ (17,929)	$ (11,157)	$ (31,993)	$ (27,874)

Condensed Statements of Opera_2

Condensed Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue not from contract with customer			$ 251
Research and development including related party	$ 12,333	$ 11,262	23,488	$ 26,033
Unrealized gain loss on derivatives	(2,352)		(2,620)
Related party [Member]
Revenue not from contract with customer	0	0	251	0
Research and development including related party	1,172	894	1,459	1,810
Unrealized gain loss on derivatives	$ 1,895	$ 0	$ 2,112	$ 0

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($) $ in Thousands	Total	SERIES A CONVERTIBLE PREFERRED STOCK [Member]	SERIES B CONVERTIBLE PREFERRED STOCK [Member]	COMMON STOCK [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	ACCUMULATED OTHER COMPREHENSIVE INCOME [Member]	ACCUMULATED DEFICIT [Member]
Beginning balance, Temporary equity (in Shares) at Dec. 31, 2022		3,673,148	2,487,237
Beginning balance, Temporary equity at Dec. 31, 2022		$ 96,767	$ 119,646
Beginning balance (in Shares) at Dec. 31, 2022				792,991
Beginning balance at Dec. 31, 2022	$ (140,696)				$ 11,895		$ (152,591)
Vesting of shares of common stock subject to repurchase, including early exercise (in Shares)				1,425
Vesting of shares of common stock subject to repurchase, including early exercise	7				7
Stock-based compensation expense	1,832				1,832
Net loss	(16,717)						(16,717)
Ending balance, Temporary equity (in Shares) at Mar. 31, 2023		3,673,148	2,487,237
Ending balance, Temporary equity at Mar. 31, 2023		$ 96,767	$ 119,646
Ending balance (in Shares) at Mar. 31, 2023				794,416
Ending balance at Mar. 31, 2023	(155,574)				13,734		(169,308)
Beginning balance, Temporary equity (in Shares) at Dec. 31, 2022		3,673,148	2,487,237
Beginning balance, Temporary equity at Dec. 31, 2022		$ 96,767	$ 119,646
Beginning balance (in Shares) at Dec. 31, 2022				792,991
Beginning balance at Dec. 31, 2022	(140,696)				11,895		(152,591)
Unrealized gain (loss) on short-term investments	127
Net loss	(28,001)
Ending balance, Temporary equity (in Shares) at Jun. 30, 2023		3,673,148	2,487,237
Ending balance, Temporary equity at Jun. 30, 2023		$ 96,767	$ 119,646
Ending balance (in Shares) at Jun. 30, 2023				805,199
Ending balance at Jun. 30, 2023	(164,255)				16,210	$ 127	(180,592)
Beginning balance, Temporary equity (in Shares) at Mar. 31, 2023		3,673,148	2,487,237
Beginning balance, Temporary equity at Mar. 31, 2023		$ 96,767	$ 119,646
Beginning balance (in Shares) at Mar. 31, 2023				794,416
Beginning balance at Mar. 31, 2023	(155,574)				13,734		(169,308)
Exercise of stock options (in Shares)				1,948
Exercise of stock options	10				10
Vesting of shares of common stock subject to repurchase, including early exercise (in Shares)				8,835
Vesting of shares of common stock subject to repurchase, including early exercise	8				8
Stock-based compensation expense	2,458				2,458
Unrealized gain (loss) on short-term investments	127					127
Net loss	(11,284)						(11,284)
Ending balance, Temporary equity (in Shares) at Jun. 30, 2023		3,673,148	2,487,237
Ending balance, Temporary equity at Jun. 30, 2023		$ 96,767	$ 119,646
Ending balance (in Shares) at Jun. 30, 2023				805,199
Ending balance at Jun. 30, 2023	(164,255)				16,210	127	(180,592)
Beginning balance, Temporary equity (in Shares) at Dec. 31, 2023		3,673,148	2,487,237
Beginning balance, Temporary equity at Dec. 31, 2023		$ 96,767	$ 119,646
Beginning balance (in Shares) at Dec. 31, 2023				809,758
Beginning balance at Dec. 31, 2023	(162,015)				18,988	308	(181,311)
Stock-based compensation expense investments	1,406				1,406
Unrealized gain (loss) on short-term investments	(101)					(101)
Net loss	(13,963)						(13,963)
Ending balance, Temporary equity (in Shares) at Mar. 31, 2024		3,673,148	2,487,237
Ending balance, Temporary equity at Mar. 31, 2024		$ 96,767	$ 119,646
Ending balance (in Shares) at Mar. 31, 2024				809,758
Ending balance at Mar. 31, 2024	(174,673)				20,394	207	(195,274)
Beginning balance, Temporary equity (in Shares) at Dec. 31, 2023		3,673,148	2,487,237
Beginning balance, Temporary equity at Dec. 31, 2023		$ 96,767	$ 119,646
Beginning balance (in Shares) at Dec. 31, 2023				809,758
Beginning balance at Dec. 31, 2023	(162,015)				18,988	308	(181,311)
Unrealized gain (loss) on short-term investments	(187)
Net loss	(31,806)
Ending balance, Temporary equity (in Shares) at Jun. 30, 2024		3,673,148	2,487,237
Ending balance, Temporary equity at Jun. 30, 2024		$ 96,767	$ 119,646
Ending balance (in Shares) at Jun. 30, 2024				814,202
Ending balance at Jun. 30, 2024	(191,097)				21,899	121	(213,117)
Beginning balance, Temporary equity (in Shares) at Mar. 31, 2024		3,673,148	2,487,237
Beginning balance, Temporary equity at Mar. 31, 2024		$ 96,767	$ 119,646
Beginning balance (in Shares) at Mar. 31, 2024				809,758
Beginning balance at Mar. 31, 2024	(174,673)				20,394	207	(195,274)
Exercise of stock options (in Shares)				4,444
Exercise of stock options	22				22
Stock-based compensation expense	1,483				1,483
Unrealized gain (loss) on short-term investments	(86)					(86)
Net loss	(17,843)						(17,843)
Ending balance, Temporary equity (in Shares) at Jun. 30, 2024		3,673,148	2,487,237
Ending balance, Temporary equity at Jun. 30, 2024		$ 96,767	$ 119,646
Ending balance (in Shares) at Jun. 30, 2024				814,202
Ending balance at Jun. 30, 2024	$ (191,097)				$ 21,899	$ 121	$ (213,117)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (31,806)	$ (28,001)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	1,190	1,116
Stock-based compensation	2,889	4,290
Change in fair value of SAFEs (including related party amounts of $2,112 and $0, respectively)	2,620
Accretion of discounts on short-term investments	(641)	(14)
Changes in operating assets and liabilities:
Accounts receivable	465	(1,692)
Other receivables (including related party amounts of $(93) and $(524), respectively)	(168)	(679)
Prepaid expenses and other current assets	(640)	1,070
Other long-term assets	62	63
Accounts payable (including related party amounts of $24 and $(148), respectively)	(103)	(72)
Accrued expenses (including related party amounts of $(1,302) and $(696), respectively)	(2,769)	(696)
Operating lease right-of-use asset and lease liabilities	130	88
Deferred revenue		(1,480)
Net cash used in operating activities	(28,771)	(26,007)
Investing activities:
Purchases of property and equipment	(482)	(2,443)
Purchases of short-term investments	(18,387)	(22,371)
Maturities of short-term investments	30,000	2,000
Net cash provided by (used in) investing activities	11,131	(22,814)
Financing activities:
Proceeds from exercise of stock options	22	10
Payments on finance leases	(78)
Cash paid in connection with deferred offering costs	(1,560)
Repurchase of restricted stock		(12)
Net cash used in financing activities	(1,616)	(2)
Net decrease in cash, cash equivalents and restricted cash	(19,256)	(48,823)
Cash, cash equivalents and restricted cash at beginning of period	53,762	102,776
Cash, cash equivalents and restricted cash at end of period	34,506	53,953
Reconciliation of cash, cash equivalents and restricted cash to the balance sheet Cash and cash equivalents	34,248	53,695
Restricted cash	258	258
Total cash, cash equivalents and restricted cash	34,506	53,953
Supplemental disclosures of noncash activities:
Property and equipment purchases in accounts payable and accrued liabilities	33	66
Deferred offering costs in accounts payable and accrued liabilities	1,280
Non-cash additions to financing leases	$ 241

Condensed Statements of Cash _2

Condensed Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Change in fair value of SAFEs including related party	$ (2,620)
Other receivables including related party	168	679
Accounts payable including related party	(103)	(72)
Accrued expenses including related party	(2,769)	(696)
Related party [Member]
Change in fair value of SAFEs including related party	2,112	0
Other receivables including related party	(93)	(524)
Accounts payable including related party	24	(148)
Accrued expenses including related party	$ (1,302)	$ (696)

Organization, Liquidity and Bas

Organization, Liquidity and Basis of Presentation	6 Months Ended
Organization, Liquidity and Basis of Presentation	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Liquidity and Basis of Presentation	1. Organization, Liquidity Organization Artiva Biotherapeutics, Inc. (the “Company”) was incorporated in the State of Delaware on February 14, 2019. The Company is a biopharmaceutical company focused on developing off-the From its inception to June 30, 2024, the Company has devoted substantially all of its resources to organizing and staffing the Company, business planning, raising capital, establishing and engaging in collaborations, performing research and development, advancing and scaling up product candidate manufacturing, establishing cold chain delivery logistics, establishing and protecting its intellectual property portfolio, and providing general and administrative support for these activities. The Company’s operations through June 30, 2024 have been funded primarily through the issuance and sale of convertible promissory notes, convertible preferred stock and simple agreements for future equity (the “SAFEs”). Liquidity Since inception through June 30, 2024, the million in upfront and reimbursable research service payments from Merck Sharp & Dohme Corp. (“Merck”). Additionally, on July 22 million (the “IPO Company’s ability to continue as a going concern as discussed in the Company’s December 31, 2023 audited financial statements as included in the Company’s prospectus dated July 18, 2024 related to its IPO filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, no longer exists. If the Company is unable to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, if ever, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue plans to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to rules and regulations of the Securities Exchange Commission for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. The results for the three and six months ended June 30, 2024 and 2023 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The unaudited condensed balance sheet as of June 30, 2024 has been derived from the financial statements as of that date but does not include all disclosures required by GAAP for complete financial statements. As all of the disclosures required by GAAP for complete financial statem ents accompanying herein should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2023 included in the Company’s prospectus dated July 18, 2024 related to its IPO filed pursuant to Rule 424(b)(4) under the Securities Act of 1933. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements as of and for the year ended December 31, 2023, included in the Company’s prospectus dated July 18, 2024 related to its IPO filed pursuant to Rule 424(b)(4) under the Securities Act of 1933. Since the date of those financial statements, there have been no changes to its significant accounting policies, except where noted below. Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Accounting estimates and management judgments reflected in the condensed financial statements include: revenue recognized, the accrual of research and development expenses, common stock, stock-based compensation, SAFEs and operating lease liabilities. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions. Short-Term Investments Short-term investments consist of debt securities, classified as available-for-sale available-for-sale As of June 30, 2024, and December 31, 2023, accrued interest receivables on short-term investments were $0.1 million and are included in prepaid expenses and other current Restricted Cash Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash as of June 30, 2024 and December 31, 2023, was $0.3 million consisting non-current Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s IPO, are capitalized and recorded in the condensed balance sheets. As of June 30, 2024 and December 31, 2023, deferred offering costs of $2.8 million and $0 million, respectively, were recorded in the condensed balance sheets. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities include shares of its convertible preferred stock, as well as outstanding stock options and restricted stock units under the Company’s equity incentive plan and have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive: AS OF JUNE 30, AS OF DECEMBER 31, 2024 2023 Convertible preferred stock 6,160,385 6,160,385 Unvested restricted stock units 22,514 22,514 Options to purchase common stock 1,803,867 1,315,726 SAFEs (1) — — Total 7,986,766 7,498,625 (1) The contingently convertible SAFEs were not included for purposes of calculating the number of diluted shares outstanding as of June 30, 2024, as the number of dilutive shares is based on a conversion ratio associated with the pricing of a future financing or liquidation event. Therefore, the contingently convertible SAFEs’ conversion ratio, and the resulting number of dilutive shares, is not determinable until the contingency is resolved. If the contingency were to have been resolved as of June 30, 2024, the number of anti-dilutive shares that would have been excluded in the calculation of dilutive net loss per share, when applying the respective conversion ratio, is estimated as 2.1 Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): 2020-06”). 2020-06 2020-06 de 2020-06 2020-06 2020-06 2020-06

Fair Value Measurements

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates their respective levels within the fair value hierarchy (in thousands): AS OF JUNE 30, 2024 CLASSIFICATION TOTAL LEVEL 1 LEVEL 2 LEVEL 3 Assets Money market funds Cash and cash equivalents $ 25,872 $ 25,872 $ — $ — Government and government agency bonds Short-term investments 12,308 — 12,308 — Total assets $ 38,180 $ 25,872 $ 12,308 $ — Liabilities SAFEs Liabilities $ 27,720 $ — $ — $ 27,720 Total liabilities $ 27,720 $ — $ — $ 27,720 AS OF DECEMBER 31, 2023 CLASSIFICATION TOTAL LEVEL 1 LEVEL 2 LEVEL 3 Assets Money market funds Cash and cash equivalents $ 28,517 $ 28,517 $ — $ — Commercial paper Short-term investments 2,090 — 2,090 — Government and government agency bonds Short-term investments 19,982 — 19,982 — Corporate bonds Short-term investments 1,395 — 1,395 — Total assets $ 51,984 $ 28,517 $ 23,467 $ — Liabilities SAFEs Liabilities $ 25,100 $ — $ — $ 25,100 Total liabilities $ 25,100 $ — $ — $ 25,100 The carrying amounts of all cash and cash equivalents, accounts receivable, other receivable, prepaid and other current assets, accounts payable, and accrued expenses are considered to be representative of their respective fair values because of the short-term nature of those instruments. Short-Term Investments The Company’s assets with a fair value categorized as Level 2 withing the fair value hierarchy consist of commercial paper, government and government agency bonds, and corporate bonds. These assets have been initially valued at the transaction price and subsequently valued at the end of each reporting period utilizing third-party pricing services. The pricing services utilize industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. Simple Agreements for Future Equity The estimated fair value of the SAFEs (see Note 7) is determined based on the aggregated, probability-weighted average of the outcomes of certain scenarios, including: (i) equity financing, with conversion of the SAFEs into a number of shares of convertible preferred stock at the lower of the post-money valuation cap price of $48.25 and the discount price (the lowest price of the standard convertible preferred stock sold in the equity financing multiplied by the specified discount rate of 85%); (ii) liquidity event (change of control, direct listing, or an initial public offering,) with mandatory conversion to common stock at the lower of post-money valuation cap price of $48.25 and discount price (price of the common stock multiplied by the discount rate of 85%); and (iii) dissolution event, with SAFE holders automatically entitled to receive cash payments equal to the purchase amount, prior to and in preference to any distribution of any assets or surplus funds to the holders of convertible preferred and common stock. On May 29, 2024, the Company executed an amendment to the SAFEs (the “SAFE Amendment”). The SAFE Amendment amended the definition of liquidity event to exclude an initial public offering and amended the definition of the discount price under an initial public offering to the lower of (a) the price per share of common stock sold to the public by the underwriters in the initial public offering multiplied by the discount rate of 85% or (b) the post-money valuation cap price of $48.25. The combined value of the probability-weighted average of those outcomes is then discounted back to each reporting period in which the SAFEs are outstanding, in each case based on a risk-adjusted discount rate estimated based on the implied interest rate using the changes in observed interest rates of corporate debt that the Company believes is appropriate for those probability-adjusted cash flows. Fair value measurements associated with SAFEs were determined based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. Increases and decreases in the fair value of the SAFEs can result from updates to assumptions such as expected timing and probability of a qualified financing event, or changes in discount rates, among other assumptions. Based on management’s assessment of the valuation of the SAFEs, performed by the Company’s third-party valuation specialists, none of the changes in the fair value of those instruments were due to changes in the Company’s own credit risk for the reporting periods presented. Judgement is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Changes or updates to assumptions could have a material impact on the reported fair value, and the change in fair value of SAFEs and the results of operations in any given period. The following tables summarize VALUATION TECHNIQUE UNOBSERVABLE INPUT AS OF JUNE 30, 2024 Liabilities SAFEs Scenario-based approach Probability weighting 5.0% - 75.0 % Discount rate 24.0 % Remaining term to event (in years) 0.05 - 0.50 VALUATION TECHNIQUE UNOBSERVABLE INPUT AS OF DECEMBER 31, 2023 Liabilities SAFEs Scenario-based approach Probability weighting 15.0% - 70.0 % Discount rate 20.1 % Remaining term to event (in years) 0.50 - 0.75 The following table summarizes the changes in fair value associated with Level 3 financial instruments held during the periods presented (in thousands): SAFEs Balance at December 31, 2023 $ 25,100 Changes in fair value of SAFEs 2,620 Balance at June 30, 2024 $ 27,720 There were no transfers to or from Level 3 during any of the periods presented.

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-term Investments	6 Months Ended
Cash, Cash Equivalents and Short-term Investments	Jun. 30, 2024
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Cash, Cash Equivalents and Short-term Investments	4. Cash, Cash Equivalents and Short-term Investments It is the Company’s policy to mitigate credit risk in its financial assets by maintaining a well-diversified portfolio that limits the amount of exposure as to maturity and investment type. All of the Company’s available-for-sale The following table summarizes the Company’s cash, cash equivalents and short-term investments for each of the periods presented (in thousands): AS OF JUNE 30, 2024 CLASSIFICATION AMORTIZED COST GROSS UNREALIZED GAINS GROSS UNREALIZED LOSSES FAIR MARKET VALU E Cash and money market funds Cash and cash equivalents $ 34,248 $ — $ — $ 34,248 Government and government agency bonds Short-term investments 12,187 121 — 12,308 Total cash, cash equivalents and short-term investments $ 46,435 $ 121 $ — $ 46,556 AS OF DECEMBER 31, 2023 CLASSIFICATION AMORTIZED COST GROSS UNREALIZED GAINS GROSS UNREALIZED LOSSES FAIR MARKET VALUE Cash and money market funds Cash and cash equivalents $ 53,504 $ — $ — $ 53,504 Commercial paper Short-term investments 2,048 42 — 2,090 Government and government agency bonds Short-term investments 19,728 254 — 19,982 Corporate bonds Short-term investments 1,383 12 — 1,395 Total cash, cash equivalents and short-term investments $ 76,663 $ 308 $ — $ 76,971 As of June 30, 2024, the Company did no amortized

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
Property and Equipment, Net	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): AS OF JUNE 30, DECEMBER 31, 2024 2023 Lab equipment $ 10,129 $ 9,760 Furniture and fixtures 872 871 Computers and software 616 607 Leasehold improvements 410 390 12,027 11,628 Less accumulated depreciation (4,712 ) (3,532 ) Total property and equipment, net $ 7,315 $ 8,096 The Company recognized $0.6 million and $1.2 million in depreciation expense for the three and six months ended June 30, 2024, respectively, and $0.5 million and $1.1 million in depreciation expense for the three and six months ended June 30, 2023, respectively.

Accrued Expenses

Accrued Expenses	6 Months Ended
Accrued Expenses	Jun. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consist of the following (in thousands): AS OF JUNE 30, DECEMBER 31, 2024 2023 Accrued research and development expenses $ 1,414 $ 2,861 Accrued payroll and other employee benefits 2,936 4,047 Other accrued expenses 1,864 1,109 Total accrued expenses $ 6,214 $ 8,017

Simple Agreement for Future Equ

Simple Agreement for Future Equity	6 Months Ended
Simple Agreement for Future Equity	Jun. 30, 2024
Simple Agreement for Future Equity [Abstract]
Simple Agreement for Future Equity	7. Simple Agreement for Future Equity During 2023, the Company entered into SAFEs with various existing investors and related parties with aggregate gross proceeds of $24.4 million. The SAFEs granted investors with rights to participate in a future equity financing. The SAFEs have no maturity dates and bear no interest. Upon an equity financing, the SAFEs will automatically convert into the type of stock issued in the financing at a per share conversion price equal to the greater of (i) the purchase amount of the SAFEs divided by the post-money valuation cap price of $48.25 per share, or (ii) the purchase amount of the SAFEs divided by the 85% per share price paid by investors in the financing. Upon an initial public offering, the SAFEs will automatically convert into shares of common stock equal to the purchase amount of the SAFE divided by the discount price (the lower of (a) the price per share of common stock sold to the public by the underwriters in the initial public offering multiplied by the discount rate of 85% or (b) the post-money valuation cap price of $48.25 per share). Other conversion events include liquidity events (a change of control or direct listing). Upon a liquidity event, each investor will automatically be entitled to receive a portion of proceeds equal to the greater of (i) the purchase amounts of the SAFEs, or (ii) the amount payable in the number of common shares equal to the purchase amount of the SAFEs divided by the 85% per share price. Upon a dissolution event and to the extent sufficient funds are available, the holders of SAFEs shall be entitled to receive cash payments equal to the purchase amount, prior to and in preference to any distribution of any assets or surplus funds to the holders of convertible preferred and common stock

Collaboration and License Agree

Collaboration and License Agreements	6 Months Ended
Collaboration and License Agreements	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and License Agreements	8. Collaboration and License Agreements The Company has entered into several agreements with GC Cell and related entities concerning its NK cell therapy platform and manufacturing of its core products, as described below. Option and License Agreement with GC Cell In September 2019, the Company entered into an option and license agreement with GC Cell Corporation (“GC Cell”), formerly Green Cross Cell Corporation, as amended in June 2020 and February 2022 (the “Core Agreement”). Under the Core Agreement, GC Cell granted the Company an exclusive, royalty-bearing license, with the right to sublicense through multiple tiers, under certain intellectual property and technology owned or controlled by GC Cell relating to non-genetically Under the Core Agreement, GC Cell agreed to conduct a discovery, research, preclinical development, and manufacturing program under a plan approved by a Joint Steering Committee (the “JSC”), to generate and identify product candidates for nomination as option candidates. GC Cell will bear all costs for its work under the R&D Plan, except that the Company will bear all costs for completing IND-enabling For each product candidate determined by the JSC to be an option candidate, the Company has an exclusive option under the Core Agreement to obtain an exclusive, sublicensable license to research, develop, manufacture and commercialize such candidate in the Artiva Territory for any therapeutic, prophylactic or diagnostic uses in humans, on economic terms to be determined in good faith by the parties. GC Cell retains exclusive rights to the licensed technology in Asia, Australia, and New Zealand, though the Company has the right to request, and GC Cell has agreed to consider in good faith, inclusion of Australia, New Zealand, and/or specific countries in Asia in the Artiva Territory on a product-by-product AB-101 (AlloNK) AB-201, AB-202, AB-205, The Company has control over and will bear the costs of the development, regulatory, manufacturing, and commercialization activities relating to the option candidates for which it has exercised its option, each a licensed product. Accordingly, the Company has certain diligence obligations and must use commercially reasonable efforts to develop and seek regulatory approval for each licensed product in at least one indication in the United States and the European Union, and following regulatory approval in a country, to commercialize such licensed product in at least one indication in such country. The Core Agreement provides that the Company has the right to engage GC Cell or its appropriate affiliate to provide research and manufacturing services for the licensed products being developed by the Company in the Artiva Territory under separately executed service agreements. Under the Core Agreement, the Company is obligated to pay a low single-digit percentage royalty on net sales of any licensed products, the manufacture, use or sale of which is claimed by or uses any Core IP. The royalty rate is subject to reduction under certain scenarios, and royalties are payable on a product-by-product country-by-country last-to-expire AB-101 In November 2019, the Company entered into a license agreement with GC Cell for its AB-101 (the “AB-101 AB-101 AB-101 AB-101. Under the AB-101 low-mid AB-101 product-by-product country-by-country AB-101 last-to-expire AB-101 not AB-201 In October 2020, the Company entered into a license agreement with GC Cell for its AB-201 (the “AB-201 AB-201 AB-201 AB-201. Under the AB-201 AB-201 product-by-product country-by-country AB-201 last-to-expire AB-201 In September 2023, the Company entered an amendment to the AB-201 AB-201 AB-201, AB-201 AB-201 product-by-product country-by-country AB-201 last-to-expire AB-201 AB-201 The AB-201 AB-201 AB-205 In December 2022, the Company entered into a license agreement with GC Cell for its AB-205 “AB-205 AB-205 AB-205 AB-205. Under the AB-205 AB-205 product-by-product country-by-country AB-205 last-to-expire AB-205 AB-205 one-time AB-205 In connection with the AB-205 Research Services Agreement with GC Cell As contemplated by the Core Agreement, in August 2020 the Company entered into the GC Cell Research Services Agreement, as amended in February 2022, under which GC Cell agreed to provide research services in support of the research and development of one or more of the products the Company has licensed from GC Cell. The agreement Master Manufacturing Agreement with GC Cell In March 2020, the Company entered into a Master Agreement for Manufacturing Services (the “Manufacturing Agreement”) with GC Cell, under which GC Cell agreed to manufacture specified products under individual work orders for use in the Company’s Phase 1 and Phase 2 clinical trials. Each work order will contain an estimated budget of service fees and out-of-pocket Merck Exclusive License and Collaboration Agreement In January 2021, the Company entered into the Exclusive License and Research Collaboration Agreement (the “Merck Collaboration Agreement”) with Merck for the discovery, development, manufacture and commercialization of CAR-NK Concurrent with entering into the Merck Collaboration Agreement, the Company also entered into an agreement with GC Cell to obtain exclusive, worldwide rights to GC Cell’s CAR-NK In October 2023, the Merck Collaboration Agreement and development thereunder was terminated by Merck. The Company applied ASC 808 to the Merck Collaboration Agreement and determined that the agreements were applicable to such guidance. The Company concluded that Merck represented a customer and applied relevant guidance from ASC 606 to account for the Merck Collaboration Agreement. In accordance with this guidance, the Company identified its performance obligations, including its grant of a license to Merck to certain of its intellectual property subject to certain conditions, transfer of technology, its conduct of research services, and its participation in a joint research committee. The Company determined that its grant of a license to Merck to certain of its intellectual property subject to certain conditions was not distinct from other performance obligations because such grant is dependent on the conduct and results of the research services. Additionally, the Company determined that its conduct of research services was not distinct from other performance obligations since the research could not be conducted without also delivering the rights to the license, developed intellectual property and technology transfer. Accordingly, the Company determined that all performance obligations should be accounted for as one combined performance obligation for each target program, and that the combined performance obligation is transferred over the expected term of the conduct of the research services, which is collectively estimated to be four years, which represents the combined terms for the research programs (“Expected Research Term”). The Company assessed the upfront, non-refundable non-creditable The Company also assessed the effects of the variable consideration under the Merck In accordance with ASC 606, the Company determined that the initial transaction price under the Merck non-refundable non-creditable The Company assessed the payments made to GC Cell in connection with the Partnered Program License Agreement and concluded that all payments received from Merck and paid to GC Cell should be reflected within the Company’s condensed financial statements on a gross basis. The Company recognized payments from Merck as collaboration revenue as the performance obligation was satisfied over time, and payments made to GC Cell were recognized as research and development expense, as incurred. Th Affimed Collaboration Agreement On November 1, 2022, the Company entered into a strategic collaboration agreement with Affimed GmbH, a subsidiary of Affimed N.V. (“Affimed”) for the clinical development and commercialization of a combination therapy, for any uses in humans or animals, comprising Affimed’s product consisting of an innate cell engager referred to as “AFM13” and the Company’s product containing an NK cell referred to as AB-101 The Company has granted Affimed, with respect to the development of the combination therapy an exclusive, and with respect to the promotion of the combination therapy under the Affimed Collaboration Agreement a non-exclusive, non-transferable non-sublicensable know-how. non-exclusive, non-transferable non-sublicensable know-how The financial terms of the Affimed Collaboration Agreement provides that Affimed shall be responsible for all costs associated with the development of the combination therapy (including all clinical trial costs), except that Affimed and the Company shall each bear 50% of the costs and expenses incurred in connection with the performance of any confirmatory combination therapy clinical trial required by the FDA. The Company shall be solely responsible for all costs incurred by the Company for the supply of AB-101 IL-2 The Company incurred $0 and $0.1 million of expense in connection with the Affimed Collaboration Agreement during the three and six months ended June 30, 2024, respectively, and $0 and $0.7 million of expense in connection with the Affimed Collaboration Agreement during the three and six months ended June 30, 2023, respectively.

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders' Deficit	6 Months Ended
Convertible Preferred Stock and Stockholders' Deficit	Jun. 30, 2024
Temporary Equity And Permanent Equity [Abstract]
Convertible Preferred Stock and Stockholders' Deficit	9. Convertible Preferred Stock and Stockholders’ Deficit Stockholders’ Deficit Under the Amended and Restated Certificate of Incorporation dated April 29, 2024, the Company had a total of 67,268,142 shares of capital stock authorized for issuance, consisting of 40,248,588 shares of common stock, par value of $0.0001 per share, and 27,019,554 shares of convertible preferred stock, par value of $0.0001 per share. The Amended and Restated Certificate of Incorporation included the authorization of 84,556 shares reserved under the terms specified as part of the Company’s Pledge 1% Movement commitment, in support of its corporate social responsibility and philanthropic pursuits. Convertible Preferred Stock In 2020 and 2021, the Company issued 2,077,165 shares and 1,595,983 shares, respectively, of Series A convertible preferred stock at a price of $21.93 per share, resulting in aggregate gross proceeds of $70.0 million and total issuance costs of $0.4 million. The Company converted a promissory note with a fair value of $10.6 million as part of the first closing and reclassified a convertible preferred stock purchase right liability with a fair value of $23.7 million into equity as part of the second closing. In 2021, the Company issued 2,487,237 shares of Series B convertible preferred stock at a price of $48.25 per share resulting in aggregate gross proceeds of $120.0 million and incurred $0.4 million of total issuance costs. As of June 30, 2024, the Company’s Series A and Series B convertible preferred stock has been classified as temporary equity in the accompanying condensed balance sheets given that the holders of the convertible preferred stock could cause certain events to occur that are outside of the Company’s control whereby the Company could be obligated to redeem the convertible preferred stock. The carrying value of the convertible preferred stock is not adjusted to the redemption value until the contingent redemption events are considered to be probable of occurring. The Company’s convertible preferred stock has the following rights, preferences and privileges: Dividends The Company shall not declare, pay or set aside any dividends on shares of any class of capital stock of the Company unless the holders of the Series A or Series B convertible preferred stock shall first receive, or simultaneously receive, a dividend on each outstanding share of the Series A convertible preferred stock equal to an amount as defined in the Company’s Amended and Restated Certificate of Incorporation. No such dividends have been declared or paid through June 30, 2024. Preferences on Liquidation The holders of the Series A convertible preferred stock are entitled to receive liquidation preferences, in the event of a change in control, at an amount per share equal to the greater of (i) the Series A original issuance price of $21.93, plus any dividends declared but unpaid or (ii) such amount per share as would have been payable had all shares of Series A convertible preferred stock been converted into common stock. The holders of the Series B convertible preferred stock are entitled to receive liquidation preferences, in the event of a change in control, at an amount per share equal to the greater of (1) the Series B original issuance price of $48.25, plus any dividends declared but unpaid or (2) such amount per share as would have been payable had all shares of Series B convertible preferred stock been converted into common stock. Liquidation payments to the holders of the Series A and Series B convertible preferred stock have priority and are made in preference to any payments to the holders of common stock. After full payment of the liquidation preference to the holders of the Series A and Series B convertible preferred stock, the remaining assets, if any, will be distributed ratably to the holders of the common stock. Conversion Rights The shares of Series A and Series B convertible preferred stock are convertible into an equal number of shares of common stock, at the option of the holder, subject to certain anti-dilution adjustments. The conversion rate for the convertible preferred stock is determined by dividing the original issue price by the conversion price. The conversion price is initially the original issue price, but is subject to adjustment for dividends, stock splits, and other distributions. The conversion rate at June 30, 2024, for the Series A and Series B convertible preferred stock was 1:1 Each share of Series A convertible preferred stock will be automatically converted into common stock at the then effective conversion rate (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the), common stock) upon: (i) the closing of the sale of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $75.0 million of gross proceeds to the Company; or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of 60% of the outstanding shares of Series A convertible preferred stock. Each share of Series B convertible preferred stock will be automatically converted into common stock at the then effective conversion rate (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to common stock) upon: (1) the closing of the sale of common stock to the public in a firm- commitment underwritten public offering pursuant to an effective registration statement Securities Act of 1933, as amended, resulting in at least $75.0 million of gross proceeds to the Company; or (2) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of 60% of the outstanding shares of Series B convertible preferred stock. Redemption Rights The holders of Series A and Series B convertible preferred stock do not have any redemption rights, except upon certain liquidation events that are outside of the Company’s control. Voting The holder of each share of Series A and Series B convertible preferred stock generally vote together with the shares of common stock as a single class, but also have class vote approval rights as provided by the Company’s certificate of incorporation or as required by applicable law. Common Stock The voting, dividend, and liquidation rights of the holders of the common stock are subject to, and qualified by, the rights, preferences and privileges of the holders of the Series A and Series B convertible preferred stock. The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. C stock reserved for future issuance consisted of the following: AS OF JUNE 30, 2024 DECEMBER 31, 2023 Convertible preferred stock 6,160,385 6,160,385 Common stock options granted and outstanding 1,803,867 1,315,726 Restricted stock units granted and outstanding 22,514 22,514 Shares available for issuance under the 2020 equity incentive plan 115,543 323,131 Shares available for issuance under the Pledge 1% commitment 84,556 84,556 Total common stock reserved for future issuance 8,186,865 7,906,312 Stock Options In June 2020, the Company adopted the 2020 Equity Incentive Plan (the “Plan”). The Plan provides for the grant of incentiv e sto non-statutory The Plan was amended in December 2020, January 2021, July 2021, August 2022, and in April 2024. In April 2024 , the Options granted under the Plan are exercisable at various dates as determined upon grant and will expire no more than 10 years from their date of grant. The exercise price of each option shall be determined by the board of directors based on the estimated fair value of the Company’s stock on the date of the option grant. The exercise price shall not be less than 100% of the fair market value of the Company’s common stock at the time the option is granted. Most option grants generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years and early exercise is permitted. The vesting period generally occurs over four years unless there is a specific performance vesting trigger at which time those shares will vest when the performance trigger is probable to occur. On April 6, 2023, the Company’s board of directors approved a stock option repricing (the “Option Repricing”) in which the exercise price of certain outstanding options to purchase shares of the Company’s common stock under the 2020 Plan was reduced to per share, the estimated fair value of the Company’s common stock as of December 31, 2022. The Option Repricing was intended to motivate holders of options with exercise prices in excess of the estimated fair value of the Company’s common stock to remain with the Company and work toward its success. The Option Repricing included options granted pursuant to the 2020 Plan that were held by, among others, members of the Company’s board of directors and the Company’s named executive officers. As a result of the Option Repricing, 1,168,651 shares of vested and unvested stock options outstanding as of April 6, 2023, with original exercise prices ranging from $5.14 to $51.72 per share, were repriced to an exercise price of $5.01 per share. The Option Repricing impacted 70 A summary of the Company’s stock option activity under the Plan is as follows: TOTAL OPTIONS WEIGHTED- AVERAGE EXERCISE PRICE PER SHARE WEIGHTED- AVERAGE REMAINING CONTRACTUAL TERM AGGREGATE INTRINSIC VALUE (in years) (in thousands) Outstanding at December 31, 2023 1,315,726 $ 5.02 9.1 $ 214 Granted 525,412 10.29 — — Exercised (4,444 ) 5.00 — — Cancelled (32,827 ) 6.76 — — Outstanding at June 30, 2024 1,803,867 $ 6.51 8.9 $ 12,540 Exercisable as of June 30, 2024 1,167,786 $ 5.04 8.0 $ 9,840 The weighted-average grant date fair value of options granted for the six months ended June 30, 2024 and 2023, was $8.59 and $1.36 per share, respectively. The total intrinsic value of options exercised during the six months ended June 30, 2024 and 2023, was de minimus. Upon the exercise of stock options, the Company will issue new shares of its common stock. Restricted Stock Unit Awards Restricted stock unit awards (“RSUs”) granted under the 2020 During the six months ended June 30, 2024 and 2023, no RSUs were granted by the Company. As of June 30, 2024, 22,514 total RSUs were outstanding. Stock-Based Compensation Expense The following table summarizes stock-based compensation expense by condensed financial statement line item in the Company’s statement of operations and comprehensive loss (in thousands): THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2024 2023 2024 2023 Research and development $ 792 $ 1,060 $ 1,559 $ 2,088 General and administrative 691 1,398 1,330 2,202 Total $ 1,483 $ 2,458 $ 2,889 $ 4,290 In 2023, the Company entered into sepa ration executives were deemed satisfied for all RSUs as of the date of separation. In order for RSUs to vest, there must be a Liquidity event and the RSUs must meet the time and service-based requirement prior to the defined Liquidity Event Deadline. The Company recognized $0 3 The Company recognized $ Ju and $ million in incremental compensation cost for the three and six months ended June 30, 2023, respectively. The assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants issued for the six months ended June 30, 2024 and 2023, were as follows: SIX MONTHS ENDED JUNE 30, 2024 2023 Stock price $ 1.18 - $3.07 $ 1.14 Risk-free rate of interest 4.1% - 4.6 % 3.6% - 3.9 % Expected term (years) 5.1 - 6.1 5.1 - 6.1 Expected stock price volatility 106.2% - 110.5 % 86.5% - 87.6 % Expected dividend yield — — As of June 30, 2024, the unrecognized compensation cost related to outstanding employee and nonemployee options was $9.9 million and is expected to be recognized as expense over a weighted-average period of 2.5 years. As of June 30, 2024, there was no unrecognized compensation cost related to outstanding RSUs.

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions GC Cell and GC Corp, subsidiaries of Green Cross Corp, are stockholders of the Company and are represented on the Company’s board of directors. In November 2019, October 2020, March 2021, and December 2022, the Company entered into a license agreement (collectively, the “License Agreements”) with GC Cell (see Note 8). In August 2020, the Company entered into a Research and Service Agreement with GC Cell in which GC Cell is to provide mutually agreed research services in support of the research and development of one or more of the Selected Products that the Company has licensed from GC Cell under the License Agreements. The Company did not incur any research and development expense in connection with the agreements for the three and six months ended June 30, 2024 and 2023. As of June 30, 2024 and December 31, 2023, the Company had no accounts payable and accrued expenses in connection with the GC Cell License Agreements and Research Service Agreement. In September 2023, the Company and GC Cell amended the AB-201 AB-201 AB-201 Under the AB-205 AB-205 AB-205 In March 2020, the Company entered into the Manufacturing Agreement with GC Cell, where GC Cell is to perform manufacturing services with respect to any biological or chemical product manufactured or to be manufactured for use in Phase 1 or Phase 2 clinical trials. The Company amended the Manufacturing Agreement in June 2020 to include the Company’s right to terminate the agreement at will. The Company incurred $1.2 million and $1.5 million of research and development expenses in connection with the agreement for the three and six months ended June 30, 2024, respectively, and $0.9 million and $1.8 million of research and development expenses in connection with the agreement for the three and six months ended June 30, 2023, respectively. As of June 30, 2024 and December 31, 2023, the Company had $1.1 million and $2.4 million, respectively, of accounts payable and accrued expenses in connection with the Manufacturing Agreement recorded in the condensed balance sheets. In January 2021, concurrent with entering into the Merck Collaboration Agreement, the Company also entered into a Partnered Program License Agreement with GC Cell to obtain exclusive, worldwide rights to GC Cell’s CAR-NK

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Operating Leases The following table presents operating rent expense and related short-term lease costs (in thousands): THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2024 2023 2024 2023 Rent expense $ 1,020 $ 952 $ 2,040 $ 2,036 Amount of rent expense related to short-term leases 73 71 147 143 Future minimum annual obligations under the Company’s operating leases with terms in excess of one year are as follows (in thousands): PERIOD ENDED JUNE 30, 2024 (remaining) 2,046 2025 4,023 2026 3,418 2027 3,520 Thereafter 5,916 Total minimum lease payments 18,923 Less: amount representing interest (3,380 ) Present value of operating lease liabilities 15,543 Less: operating lease liabilities, current (3,674 ) Operating lease liabilities, net of current portion $ 11,869 As the Company’s leases do not provide an implicit rate, the Company uses an in AS OF JUNE 30, DECEMBER 31, 2024 2023 Weighted-average remaining lease term 5.0 years 5.3 years Weighted-average discount rate 7.8 % 7.8 % On July 22, 2022, the Company entered into a sublease (the “Sublease Agreement”) with Origis Operating Services, LLC, (the “Sublessee”), whereby the Company agreed to sublease to Sublessee all of the 13,405 rentable square feet of office space in San Diego, California The expected undiscounted cash flows to be received from PERIOD ENDED JUNE 3 0 2024 (remaining) $ 429 2025 873 Total $ 1,302 The Company recognized $0.2 million and $0.4 million of sublease income for the three and six months ended June 30, 2024, respectively and $0.2 million and $0.4 million of sublease income for the three and six months ended June 30, 2023, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events For the purposes of the condensed financial statements as of June 30, 2024, and the three and six months then ended, the Company has evaluated the subsequent events through August 30, 2024, the date the condensed financial statements were issued. On July 12, 2024, the Company effected a 1-for-4.386 On July 22 underwriters an option for a period additional shares of common stock. On July 25, 2024, the underwriters partially exercised their 30-day shares of the Company’s common stock at the IPO price, upon which the Company received net proceeds of approximately million. All underwriter discounts and commissions, fees, and expenses, including the previously deferred offering costs as disclosed previously in this Quarterly Report, will be charged to additional paid in capital as recorded against the gross proceeds. In connection with the closing of the IPO, the Company’s outstanding convertible SAFE shares automatically converted into 2,391,418 shares of common stock, and the Company’s outstanding convertible preferred stock automatically converted into 6,160,385 shares of common stock. In connection with the closing of the IPO, the Company’s board of directors adopted the 2024 Equity Inventive Plan (the “2024 Plan”), a successor to and continuation of the 2020 Plan (as defined in Note 9), and the 2024 Employe Stock Purchase Plan (the “2024 ESPP”). Upon the effectiveness of the 2024 Plan, 4,572,025 shares of common stock were authorized for issuance which consists of (1) 2,630,000 new shares of common stock, (2) 115,436 shares available for issuance under the 2020 Plan, and (3) up to 1,826,589 shares of common stock subject to outstanding stock awards granted under the 2020 Plan that, on or after the 2024 Plan becomes effective, expire or otherwise terminate prior to exercise or settlement; are not issued because the stock award is settled in cash; are forfeited or repurchased because of the failure to vest; or are reacquired or withheld to satisfy a tax withholding obligation or the purchase or exercise price, if any, as such shares become available from time to time. Furthermore, upon effectiveness of the 2024 Plan, no further grants will be made under the 2020 Plan, and the 2020 Plan will automatically terminate on June 23, 2030 .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Accounting estimates and management judgments reflected in the condensed financial statements include: revenue recognized, the accrual of research and development expenses, common stock, stock-based compensation, SAFEs and operating lease liabilities. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
Short-Term Investments	Short-Term Investments Short-term investments consist of debt securities, classified as available-for-sale available-for-sale As of June 30, 2024, and December 31, 2023, accrued interest receivables on short-term investments were $0.1 million and are included in prepaid expenses and other current
Restricted Cash	Restricted Cash Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash as of June 30, 2024 and December 31, 2023, was $0.3 million consisting non-current
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s IPO, are capitalized and recorded in the condensed balance sheets. As of June 30, 2024 and December 31, 2023, deferred offering costs of $2.8 million and $0 million, respectively, were recorded in the condensed balance sheets.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities include shares of its convertible preferred stock, as well as outstanding stock options and restricted stock units under the Company’s equity incentive plan and have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive: AS OF JUNE 30, AS OF DECEMBER 31, 2024 2023 Convertible preferred stock 6,160,385 6,160,385 Unvested restricted stock units 22,514 22,514 Options to purchase common stock 1,803,867 1,315,726 SAFEs (1) — — Total 7,986,766 7,498,625 (1) The contingently convertible SAFEs were not included for purposes of calculating the number of diluted shares outstanding as of June 30, 2024, as the number of dilutive shares is based on a conversion ratio associated with the pricing of a future financing or liquidation event. Therefore, the contingently convertible SAFEs’ conversion ratio, and the resulting number of dilutive shares, is not determinable until the contingency is resolved. If the contingency were to have been resolved as of June 30, 2024, the number of anti-dilutive shares that would have been excluded in the calculation of dilutive net loss per share, when applying the respective conversion ratio, is estimated as 2.1
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): 2020-06”). 2020-06 2020-06 de 2020-06 2020-06 2020-06 2020-06

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
Summary of Significant Accounting Policies (Tables)	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of anti-dilutive securities excluded from calculation of earnings per share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive: AS OF JUNE 30, AS OF DECEMBER 31, 2024 2023 Convertible preferred stock 6,160,385 6,160,385 Unvested restricted stock units 22,514 22,514 Options to purchase common stock 1,803,867 1,315,726 SAFEs (1) — — Total 7,986,766 7,498,625 (1) The contingently convertible SAFEs were not included for purposes of calculating the number of diluted shares outstanding as of June 30, 2024, as the number of dilutive shares is based on a conversion ratio associated with the pricing of a future financing or liquidation event. Therefore, the contingently convertible SAFEs’ conversion ratio, and the resulting number of dilutive shares, is not determinable until the contingency is resolved. If the contingency were to have been resolved as of June 30, 2024, the number of anti-dilutive shares that would have been excluded in the calculation of dilutive net loss per share, when applying the respective conversion ratio, is estimated as 2.1

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Summary of assets and liabilities measured at fair value on recurring basis	The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates their respective levels within the fair value hierarchy (in thousands): AS OF JUNE 30, 2024 CLASSIFICATION TOTAL LEVEL 1 LEVEL 2 LEVEL 3 Assets Money market funds Cash and cash equivalents $ 25,872 $ 25,872 $ — $ — Government and government agency bonds Short-term investments 12,308 — 12,308 — Total assets $ 38,180 $ 25,872 $ 12,308 $ — Liabilities SAFEs Liabilities $ 27,720 $ — $ — $ 27,720 Total liabilities $ 27,720 $ — $ — $ 27,720 AS OF DECEMBER 31, 2023 CLASSIFICATION TOTAL LEVEL 1 LEVEL 2 LEVEL 3 Assets Money market funds Cash and cash equivalents $ 28,517 $ 28,517 $ — $ — Commercial paper Short-term investments 2,090 — 2,090 — Government and government agency bonds Short-term investments 19,982 — 19,982 — Corporate bonds Short-term investments 1,395 — 1,395 — Total assets $ 51,984 $ 28,517 $ 23,467 $ — Liabilities SAFEs Liabilities $ 25,100 $ — $ — $ 25,100 Total liabilities $ 25,100 $ — $ — $ 25,100
Summary of significant inputs not observable in the fair value measurements	The following tables summarize VALUATION TECHNIQUE UNOBSERVABLE INPUT AS OF JUNE 30, 2024 Liabilities SAFEs Scenario-based approach Probability weighting 5.0% - 75.0 % Discount rate 24.0 % Remaining term to event (in years) 0.05 - 0.50 VALUATION TECHNIQUE UNOBSERVABLE INPUT AS OF DECEMBER 31, 2023 Liabilities SAFEs Scenario-based approach Probability weighting 15.0% - 70.0 % Discount rate 20.1 % Remaining term to event (in years) 0.50 - 0.75
Summary of changes in fair value associated with level 3 financial instruments	The following table summarizes the changes in fair value associated with Level 3 financial instruments held during the periods presented (in thousands): SAFEs Balance at December 31, 2023 $ 25,100 Changes in fair value of SAFEs 2,620 Balance at June 30, 2024 $ 27,720

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-term Investments (Tables)	6 Months Ended
Cash, Cash Equivalents and Short-term Investments (Tables)	Jun. 30, 2024
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Summary of company's cash and cash equivalents and short-term investments	The following table summarizes the Company’s cash, cash equivalents and short-term investments for each of the periods presented (in thousands): AS OF JUNE 30, 2024 CLASSIFICATION AMORTIZED COST GROSS UNREALIZED GAINS GROSS UNREALIZED LOSSES FAIR MARKET VALU E Cash and money market funds Cash and cash equivalents $ 34,248 $ — $ — $ 34,248 Government and government agency bonds Short-term investments 12,187 121 — 12,308 Total cash, cash equivalents and short-term investments $ 46,435 $ 121 $ — $ 46,556 AS OF DECEMBER 31, 2023 CLASSIFICATION AMORTIZED COST GROSS UNREALIZED GAINS GROSS UNREALIZED LOSSES FAIR MARKET VALUE Cash and money market funds Cash and cash equivalents $ 53,504 $ — $ — $ 53,504 Commercial paper Short-term investments 2,048 42 — 2,090 Government and government agency bonds Short-term investments 19,728 254 — 19,982 Corporate bonds Short-term investments 1,383 12 — 1,395 Total cash, cash equivalents and short-term investments $ 76,663 $ 308 $ — $ 76,971

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
Property and Equipment, Net (Tables)	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of property and equipment of net consisted	Property and equipment, net consisted of the following (in thousands): AS OF JUNE 30, DECEMBER 31, 2024 2023 Lab equipment $ 10,129 $ 9,760 Furniture and fixtures 872 871 Computers and software 616 607 Leasehold improvements 410 390 12,027 11,628 Less accumulated depreciation (4,712 ) (3,532 ) Total property and equipment, net $ 7,315 $ 8,096

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
Accrued Expenses (Tables)	Jun. 30, 2024
Accrued Liabilities, Current [Abstract]
Summary of accrued expenses	Accrued expenses consist of the following (in thousands): AS OF JUNE 30, DECEMBER 31, 2024 2023 Accrued research and development expenses $ 1,414 $ 2,861 Accrued payroll and other employee benefits 2,936 4,047 Other accrued expenses 1,864 1,109 Total accrued expenses $ 6,214 $ 8,017

Convertible Preferred Stock a_2

Convertible Preferred Stock and Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2024
Temporary Equity And Permanent Equity [Abstract]
Summary of common stock reserved for future issuance	C stock reserved for future issuance consisted of the following: AS OF JUNE 30, 2024 DECEMBER 31, 2023 Convertible preferred stock 6,160,385 6,160,385 Common stock options granted and outstanding 1,803,867 1,315,726 Restricted stock units granted and outstanding 22,514 22,514 Shares available for issuance under the 2020 equity incentive plan 115,543 323,131 Shares available for issuance under the Pledge 1% commitment 84,556 84,556 Total common stock reserved for future issuance 8,186,865 7,906,312
Summary of company's stock option activity under the plan	A summary of the Company’s stock option activity under the Plan is as follows: TOTAL OPTIONS WEIGHTED- AVERAGE EXERCISE PRICE PER SHARE WEIGHTED- AVERAGE REMAINING CONTRACTUAL TERM AGGREGATE INTRINSIC VALUE (in years) (in thousands) Outstanding at December 31, 2023 1,315,726 $ 5.02 9.1 $ 214 Granted 525,412 10.29 — — Exercised (4,444 ) 5.00 — — Cancelled (32,827 ) 6.76 — — Outstanding at June 30, 2024 1,803,867 $ 6.51 8.9 $ 12,540 Exercisable as of June 30, 2024 1,167,786 $ 5.04 8.0 $ 9,840
Summary of stock-based compensation expense	The following table summarizes stock-based compensation expense by condensed financial statement line item in the Company’s statement of operations and comprehensive loss (in thousands): THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2024 2023 2024 2023 Research and development $ 792 $ 1,060 $ 1,559 $ 2,088 General and administrative 691 1,398 1,330 2,202 Total $ 1,483 $ 2,458 $ 2,889 $ 4,290
Summary of black-scholes option pricing model	The assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants issued for the six months ended June 30, 2024 and 2023, were as follows: SIX MONTHS ENDED JUNE 30, 2024 2023 Stock price $ 1.18 - $3.07 $ 1.14 Risk-free rate of interest 4.1% - 4.6 % 3.6% - 3.9 % Expected term (years) 5.1 - 6.1 5.1 - 6.1 Expected stock price volatility 106.2% - 110.5 % 86.5% - 87.6 % Expected dividend yield — —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
Commitments and Contingencies (Tables)	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Summary of operating rent expenses	The following table presents operating rent expense and related short-term lease costs (in thousands): THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2024 2023 2024 2023 Rent expense $ 1,020 $ 952 $ 2,040 $ 2,036 Amount of rent expense related to short-term leases 73 71 147 143
Summary of future minimum annual obligations under the company's operating leases	Future minimum annual obligations under the Company’s operating leases with terms in excess of one year are as follows (in thousands): PERIOD ENDED JUNE 30, 2024 (remaining) 2,046 2025 4,023 2026 3,418 2027 3,520 Thereafter 5,916 Total minimum lease payments 18,923 Less: amount representing interest (3,380 ) Present value of operating lease liabilities 15,543 Less: operating lease liabilities, current (3,674 ) Operating lease liabilities, net of current portion $ 11,869
Summary of incremental borrowing rate	As the Company’s leases do not provide an implicit rate, the Company uses an in AS OF JUNE 30, DECEMBER 31, 2024 2023 Weighted-average remaining lease term 5.0 years 5.3 years Weighted-average discount rate 7.8 % 7.8 %
Summary of expected undiscounted cashflow	The expected undiscounted cash flows to be received from PERIOD ENDED JUNE 3 0 2024 (remaining) $ 429 2025 873 Total $ 1,302

Organization, Liquidity and B_2

Organization, Liquidity and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Jul. 22, 2024	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Date of incorporation			Feb. 14, 2019
Retained earnings accumulated deficit		$ (213,117)	$ (213,117)		$ (181,311)
Cash flow from used in operating activities			(28,771)	$ (26,007)
Cash and cash equivalents current		34,248	34,248	$ 53,695	53,504
Short-term investments		12,308	12,308		$ 23,467
Cumulative gross proceeds from convertible notes derivative instruments and redeemable convertible preferred stock		222,400	222,400
Subsequent event [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from issuance initial public offering	$ 161,900
Merck exclusive license and collaboration agreement [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Receipt From The Counterparty		$ 39,900	$ 39,900

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Addition Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Accounting Policies [Line Items]
Accrued interest receivables on short-term investments	$ 100	$ 100
Restricted cash	258	258	$ 258
Deferred offering costs	$ 2,840	$ 0
Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current, Statement of Financial Position [Extensible Enumeration]	Prepaid Expense and Other Assets, Current	Prepaid Expense and Other Assets, Current
Letter of credit [Member]
Accounting Policies [Line Items]
Restricted cash	$ 300	$ 300

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Anti-dilutive Securities Excluded from Calculation of Earnings Per Share (Detail) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of earnings per share	7,986,766	7,498,625
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of earnings per share	6,160,385	6,160,385
Unvested restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of earnings per share	22,514	22,514
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of earnings per share	1,803,867	1,315,726
SAFEs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of earnings per share

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Anti-dilutive Securities Excluded from Calculation of Earnings Per Share (Parenthetical) (Detail) shares in Millions	6 Months Ended
	Jun. 30, 2024 shares
Accounting Policies [Abstract]
Anti-dilutive securities value excluded from the calculation of earnings per share value	2.1

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 34,248
Recurring [Member]
Assets
Total assets	38,180	$ 51,984
Liabilities
Liabilities	27,720	25,100
Total liabilities	27,720	25,100
Money market funds [Member] \| Recurring [Member]
Assets
Cash and cash equivalents	25,872	28,517
Commercial paper [Member] \| Recurring [Member]
Assets
Short-term investments		2,090
Government and government agency bonds [Member] \| Recurring [Member]
Assets
Short-term investments	12,308	19,982
Corporate bonds [Member] \| Recurring [Member]
Assets
Short-term investments		1,395
Level 1 [Member] \| Recurring [Member]
Assets
Total assets	25,872	28,517
Level 1 [Member] \| Money market funds [Member] \| Recurring [Member]
Assets
Cash and cash equivalents	25,872	28,517
Level 2 [Member] \| Recurring [Member]
Assets
Total assets	12,308	23,467
Level 2 [Member] \| Commercial paper [Member] \| Recurring [Member]
Assets
Short-term investments		2,090
Level 2 [Member] \| Government and government agency bonds [Member] \| Recurring [Member]
Assets
Short-term investments	12,308	19,982
Level 2 [Member] \| Corporate bonds [Member] \| Recurring [Member]
Assets
Short-term investments		1,395
Level 3 [Member] \| Recurring [Member]
Liabilities
Liabilities	27,720	25,100
Total liabilities	$ 27,720	$ 25,100

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - Simple agreement for future equity [Member] - $ / shares	Jun. 30, 2024	May 29, 2024	May 28, 2024
Equity financing [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative cap price	48.25		48.25
Discount rate on issuance of common stock	85%		85%
Liquidity event [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative cap price	48.25		48.25
Discount rate on issuance of common stock	85%		85%
Excluding liquidity event [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative cap price		48.25
Discount rate on issuance of common stock	85%	85%

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Significant Inputs Not Observable in the Fair Value Measurements (Detail) - SAFE [Member] - Scenario-based approach [Member]	Jun. 30, 2024 yr	Dec. 31, 2023 yr
Discount rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	0.24	0.201
Minimum [Member] \| Probability weighting [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	0.05	0.15
Minimum [Member] \| Remaining term to event (in years) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	0.05	0.5
Maximum [Member] \| Probability weighting [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	0.75	0.70
Maximum [Member] \| Remaining term to event (in years) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	0.5	0.75

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Changes in Fair Value Associated With Level 3 Financial Instruments (Detail) - Simple agreement for future equity [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 25,100
Changes in fair value of SAFEs	2,620
Ending Balance	$ 27,720

Cash, Cash Equivalents and Sh_3

Cash, Cash Equivalents and Short-term Investments - Summary of Company's Cash and Cash Equivalents and Short-term Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents, Amortized Cost	$ 34,248	$ 53,504	$ 53,695
Total cash, cash equivalents and short-term investments, Amortized Cost	46,435	76,663
Gross Unrealized Gains	121	308
Cash and cash equivalents, Fair Market Value	34,248
Total cash, cash equivalents and short-term investments, Fair Market Value	46,556	76,971
Cash and money market funds [Member]
Debt Securities, Available-for-Sale [Line Items]
Cash and cash equivalents, Amortized Cost		53,504
Cash and cash equivalents, Fair Market Value		53,504
Commercial paper [Member]
Debt Securities, Available-for-Sale [Line Items]
Short-term investments, Amortized Cost		2,048
Gross Unrealized Gains		42
Short-term investments, Fair Market Value		2,090
Government and government agency bonds [Member]
Debt Securities, Available-for-Sale [Line Items]
Short-term investments, Amortized Cost	12,187	19,728
Gross Unrealized Gains	121	254
Short-term investments, Fair Market Value	$ 12,308	19,982
Corporate bonds [Member]
Debt Securities, Available-for-Sale [Line Items]
Short-term investments, Amortized Cost		1,383
Gross Unrealized Gains		12
Short-term investments, Fair Market Value		$ 1,395

Cash, Cash Equivalents and Sh_4

Cash, Cash Equivalents and Short-term Investments - Additional Information (Detail) $ in Thousands	Jun. 30, 2024 USD ($)
Cash Equivalents And Short Term Investments [Abstract]
Allowance for credit losses	$ 0

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment of Net Consisted (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment	$ 12,027	$ 11,628
Less accumulated depreciation	(4,712)	(3,532)
Total property and equipment, net	7,315	8,096
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	10,129	9,760
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	872	871
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	616	607
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 410	$ 390

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 0.6	$ 0.5	$ 1.2	$ 1.1

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued research and development expenses	$ 1,414	$ 2,861
Accrued payroll and other employee benefits	2,936	4,047
Other accrued expenses	1,864	1,109
Total accrued expenses	$ 6,214	$ 8,017

Simple Agreement for Future E_2

Simple Agreement for Future Equity - Additional Information (Detail) - Simple agreement for future equity [Member] $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares	May 29, 2024 $ / shares	May 28, 2024 $ / shares
Option Indexed to Issuer's Equity [Line Items]
Proceeds from Related Party Debt \| $	$ 24.4
Equity financing [Member]
Option Indexed to Issuer's Equity [Line Items]
Derivative cap price	48.25		48.25
Discount rate on issuance of common stock	85%		85%
Liquidity event [Member]
Option Indexed to Issuer's Equity [Line Items]
Derivative cap price	48.25		48.25
Discount rate on issuance of common stock	85%		85%
Excluding liquidity event [Member]
Option Indexed to Issuer's Equity [Line Items]
Derivative cap price		48.25
Discount rate on issuance of common stock	85%	85%

Collaboration and License Agr_2

Collaboration and License Agreements - Additional Information (Detail) $ in Thousands			1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) Units	Feb. 28, 2022 USD ($)	Nov. 30, 2022	Jan. 31, 2021 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue not from contract with customer							$ 251
Accounts receivable net current	$ 569				$ 569		569		$ 1,034
Other receivable current	$ 892				892		892		724
Option And License Agreement With GC Cell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of products units for which the option has been exercised by the company \| Units	4
Royalty percentage to be paid by the counterparty	50%
AB-101 Selected Product License Agreement with GC cell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage to be paid by the counterparty		50%
AB-101 Selected Product License Agreement with GC cell [Member] \| Development milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone amount payable		$ 22,000
AB-101 Selected Product License Agreement with GC cell [Member] \| Sales milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone amount payable		$ 55,000
Milestone Amount Recognized					0
Royaly expenses recognized					0
AB-201 Selected Product License Agreement with GC cell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage to be paid by the counterparty		50%
Revenue not from contract with customer					0		300
Accounts receivable net current	$ 600				600		600		600
AB-201 Selected Product License Agreement with GC cell [Member] \| Development milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone amount payable		$ 25,000
Milestone payment receivable										$ 1,800
AB-201 Selected Product License Agreement with GC cell [Member] \| Sales milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone amount payable		$ 55,000
AB-205 Selected Product License Agreement with GC cell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royaly expenses recognized					0
Accounts receivable net current											$ 2,500
Research and development expenses reimbursed					0	$ 500	100	$ 500
Other receivable current	$ 700				700		700		$ 600
AB-205 Selected Product License Agreement with GC cell [Member] \| Development milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone amount payable											29,500
AB-205 Selected Product License Agreement with GC cell [Member] \| Sales milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment receivable											$ 28,000
Merck exclusive license and collaboration agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received				$ 30,000
Upfront payment received and non refundable				$ 30,000
Performance obligation transaction price												$ 58,000
Contract with customer liability												30,000
Performance obligation transaction price towards research and development fees												$ 28,000
Contract with customer liability revenue recognized					0	3,500	0	4,500
Receipt from the counterparty					39,900		39,900
Upfront fee received					30,000
Upfront fee received related to reimbursable research services					$ 9,900
Partnered program licensing agreement with GC cell [Member] \| Products in asia australia and new zealand [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment percentage				100%
Partnered program licensing agreement with GC cell [Member] \| Products in other territories [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment percentage				50%
Affimed collaboration agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of costs to be incurred in connection with the performance of confimatory combination			50%
Percentage of costs to be borne by the counterparty			50%
Revenue share of the company in percentage					67%
Revenue share of the counterparty in percentage					33%
Expenses incurred in connection with the agreement					$ 0	$ 0	$ 100	$ 700

Convertible Preferred Stock a_3

Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) $ / shares in Units, $ in Thousands			3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares	Apr. 05, 2023 $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 $ / shares shares	Apr. 30, 2024 shares	Apr. 29, 2024 $ / shares shares	Apr. 06, 2023 $ / shares
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Stock shares authorized temporary and permanent shares											67,268,142
Common stock shares authorized											40,248,588
Common stock par or stated value per share \| $ / shares											$ 0.0001
Temporary equity shares authorized											27,019,554
Temporary equity par or stated value per share \| $ / shares											$ 0.0001
Common stock shares reserved for future issuance	8,186,865		8,186,865		8,186,865		7,906,312
Movement commitement percentage											1%
Warrant liability converted into equity value \| $								$ 23,700
Temporary equity dividend declared \| $					$ 0
Share-based payment arrangement, option [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Common stock shares reserved for future issuance	1,803,867		1,803,867		1,803,867		1,315,726
Restricted stock units (RSUs) [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Common stock shares reserved for future issuance	22,514		22,514		22,514		22,514
2024 amended equity incentive plan [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Common stock shares reserved for future issuance										2,083,797
Share based compensation by share based award exercise price of options outstanding \| $ / shares	$ 6.51		$ 6.51		$ 6.51		$ 5.02
Share based compensation by share based award equity instruments other than options outstanding non vested	1,803,867		1,803,867		1,803,867		1,315,726
Share based compensation non vested stock options cost not yet recognized \| $	$ 9,900		$ 9,900		$ 9,900
2024 amended equity incentive plan [Member] \| Share-based payment arrangement, option [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Share based compensation by share based award expiration period					10 years
Share based compensation by share based award purchase price of common stock as a percentage of market fair value					100%
Share based compensation by share based award vesting rights percentage					25%
Share based compensation by share based award vesting period					4 years
Share based compensation by share based award exercise price of options outstanding \| $ / shares												$ 5.01
Share based compensation by shares based award number of options for which exercise price was modified during the period		1,168,651
Share based compensation shares authorized under stock option plans exercise price range lower range limit \| $ / shares		$ 5.14
Share based compensation shares authorized under stock option plans exercise price range upper range limit \| $ / shares		$ 51.72
Share based compensation by share based payment award modification incremental cost \| $							$ 1,500
Share based compensation non vested award cost not yet recognized period for recognition					2 years 6 months
Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price \| $ / shares												$ 5.01
2024 amended equity incentive plan [Member] \| Restricted stock units (RSUs) [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Share based compensation by share based award equity instruments other than options granted during the period					0	0
Share based compensation by share based award equity instruments other than options outstanding non vested	22,514		22,514		22,514
Share based compensation by share based compensation equity instruments other than options cost not yet recognized \| $	$ 0		$ 0		$ 0
Separation agreement with certain executives terminating employment [Member] \| Share-based payment arrangement, option [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Share based compensation by share based payment award modification incremental cost \| $			0	$ 0	0	$ 200
Separation agreement with certain executives terminating employment [Member] \| Restricted stock units (RSUs) [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Share based compensation by share based payment award modification incremental cost \| $			$ 0	$ 500	$ 0	$ 500
Class a redeemable convertible preferred stock [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Temporary equity stock issued during the period shares new issues								1,595,983	2,077,165
Temporary equity issue price per share \| $ / shares								$ 21.93	$ 21.93
Cumulative gross proceeds form redeemable preferred convertible preferred stock \| $								$ 70,000
Redeemable convertible preferred stock issuance costs cumulative \| $								400
Temporary equity liquidation preference per share \| $ / shares	$ 21.93		$ 21.93		$ 21.93
Gross proceeds minimum firm underwriteen public offring for conversion of temporary equity into permanent equity \| $	$ 75,000
Votes as a percentage of redeemable preferred stock outstanding needed for conversion into permanent equity	60%		60%		60%
Convertible notes payable [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Stock issued during the period conversion of convertible notes value \| $								10,600
Series b redeemable convertible preferred stock [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Temporary equity shares authorized	10,909,091		10,909,091		10,909,091		10,909,091
Temporary equity par or stated value per share \| $ / shares	$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001
Cumulative gross proceeds form redeemable preferred convertible preferred stock \| $								120,000
Redeemable convertible preferred stock issuance costs cumulative \| $								$ 400
Temporary equity liquidation preference per share \| $ / shares	$ 48.25		$ 48.25		$ 48.25
Gross proceeds minimum firm underwriteen public offring for conversion of temporary equity into permanent equity \| $	$ 75,000
Votes as a percentage of redeemable preferred stock outstanding needed for conversion into permanent equity	60%		60%		60%
Temporary equity shares issued	2,487,237		2,487,237		2,487,237		2,487,237	2,487,237
Shares issued, price per share \| $ / shares								$ 48.25
Class A and class B redeemable convertible preferred stock [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Stock split ratio for the conversion from temporary equity into permanent equity	1
One percent movement commitment [Member]
Disclosure In Entirety Of Temporary And Permanent Equity [Line Items]
Common stock shares reserved for future issuance											84,556

Convertible Preferred Stock a_4

Convertible Preferred Stock and Stockholders' Deficit - Summary of Common Stock Reserved for Future Issuance (Detail) - shares	Jun. 30, 2024	Dec. 31, 2023
Disclosure In Tabular Form Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	8,186,865	7,906,312
Shares available for issuance under the pledge one percent commitement [Member]
Disclosure In Tabular Form Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	84,556	84,556
2020 equity incentive plan [Member]
Disclosure In Tabular Form Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	115,543	323,131
Share-based payment arrangement, option [Member]
Disclosure In Tabular Form Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	1,803,867	1,315,726
Restricted stock units (RSUs) [Member]
Disclosure In Tabular Form Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	22,514	22,514
Redeemable convertible preferred stock [Member]
Disclosure In Tabular Form Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	6,160,385	6,160,385

Convertible Preferred Stock a_5

Convertible Preferred Stock and Stockholders' Deficit - Summary of Company's Stock Option Activity Under the Plan (Detail) - 2024 amended equity incentive plan [Member] $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding at December 31, 2023 \| shares	1,315,726
Granted \| shares	525,412
Exercised \| shares	(4,444)
Cancelled \| shares	(32,827)
Outstanding at June 30, 2024 \| shares	1,803,867	1,315,726
Exercisable as of June 30, 2024 \| shares	1,167,786
Outstanding at December 31, 2023 \| $ / shares	$ 5.02
Granted \| $ / shares	10.29
Exercised \| $ / shares	5
Cancelled \| $ / shares	6.76
Outstanding at June 30, 2024 \| $ / shares	6.51	$ 5.02
Exercisable as of June 30, 2024 \| $ / shares	$ 5.04
Weighted - average remaining contractual term	8 years 10 months 24 days	9 years 1 month 6 days
Weighted - average remaining contractual term	8 years
Aggregate intrinsic value \| $	$ 12,540	$ 214
Aggregate intrinsic value \| $	$ 9,840

Convertible Preferred Stock a_6

Convertible Preferred Stock and Stockholders' Deficit - Summary of Company's Stock Option Activity Under the Plan (Parenthetical) (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
2024 amended equity incentive plan [Member] \| Share-based payment arrangement, option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation by share based award weighted average fair value of options granted during the period	$ 8.59	$ 1.36

Convertible Preferred Stock a_7

Convertible Preferred Stock and Stockholders' Deficit - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 1,483	$ 2,458	$ 2,889	$ 4,290
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	792	1,060	1,559	2,088
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 691	$ 1,398	$ 1,330	$ 2,202

Convertible Preferred Stock a_8

Convertible Preferred Stock and Stockholders' Deficit - Summary of Black-Scholes Option Pricing Model (Detail) - 2024 amended equity incentive plan [Member] - Share-based payment arrangement, option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock price		$ 1.14
Maximum [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock price	$ 3.07
Risk-free rate of interest	4.60%	3.90%
Expected term (years)	6 years 1 month 6 days	6 years 1 month 6 days
Expected stock price volatility	110.50%	87.60%
Minimum [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock price	$ 1.18
Risk-free rate of interest	4.10%	3.60%
Expected term (years)	5 years 1 month 6 days	5 years 1 month 6 days
Expected stock price volatility	106.20%	86.50%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jan. 31, 2021
Related Party Transaction [Line Items]
Research and development expenses	$ 12,333	$ 11,262	$ 23,488	$ 26,033
Revenue not from contract with customer			251
Accounts receivable net current	569		569		$ 1,034
Other receivable current	892		892		724
GC cell [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities current					0
GC cell [Member] \| Research and service agreement one [Member]
Related Party Transaction [Line Items]
Research and development expenses	0	0	0	0
Accounts payable and accrued liabilities current	0		0
GC cell [Member] \| Option and license agreement for AB 201 selected product as amended [Member]
Related Party Transaction [Line Items]
Revenue not from contract with customer	0		300
Accounts receivable net current	600		600		600
GC cell [Member] \| AB two hundred and five selected product license agreement [Member]
Related Party Transaction [Line Items]
Research and development expenses reimbursed	0	500	100	500
Other receivable current	700		700		600
GC cell [Member] \| Manufacturing agreement [Member]
Related Party Transaction [Line Items]
Research and development expenses	1,200	$ 900	1,500	$ 1,800
Accounts payable and accrued liabilities current	$ 1,100		$ 1,100		$ 2,400
GC cell [Member] \| Partnered program licensing agreement [Member] \| Products in asia australia and new zealand [Member]
Related Party Transaction [Line Items]
Milestone payment percentage						100%
GC cell [Member] \| Partnered program licensing agreement [Member] \| Products in other territories [Member]
Related Party Transaction [Line Items]
Milestone payment percentage						50%

Commitments and Contingencies -

Commitments and Contingencies - Summary of Operating Rent Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Rent expense	$ 1,020	$ 952	$ 2,040	$ 2,036
Amount of rent expense related to short-term leases	$ 73	$ 71	$ 147	$ 143

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Future Minimum Annual Obligations Under the Company's Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (remaining)	$ 2,046
2025	4,023
2026	3,418
2027	3,520
Thereafter	5,916
Total minimum lease payments	18,923
Less: amount representing interest	(3,380)
Present value of operating lease liabilities	15,543
Less: operating lease liabilities, current	(3,674)	$ (3,596)
Operating lease liabilities, net of current portion	$ 11,869	$ 13,316

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Incremental Borrowing Rate (Detail)	Jun. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted-average remaining lease term	5 years	5 years 3 months 18 days
Weighted-average discount rate	7.80%	7.80%

Commitments and Contingencies_4

Commitments and Contingencies - Additional Information (Detail) $ in Millions		3 Months Ended		6 Months Ended
	Jul. 22, 2022 USD ($) ft²	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Other Commitments [Line Items]
Sublease income		$ 0.2	$ 0.2	$ 0.4	$ 0.4
Office space [Member]
Other Commitments [Line Items]
Area of sublessee \| ft²	13,405
Operating sublease monthly rent	$ 2.6
Office space [Member] \| Minimum [Member]
Other Commitments [Line Items]
Operating sublease date of commencement of contract	Aug. 01, 2022
Office space [Member] \| Maximum [Member]
Other Commitments [Line Items]
Operating sublease expirary date of contract	Dec. 31, 2025

Commitments and Contingencies_5

Commitments and Contingencies - Summary of Expected Undiscounted Cashflow (Detail) $ in Thousands	Jun. 30, 2024 USD ($)
Leases [Abstract]
2024 (remaining)	$ 429
2025	873
Total	$ 1,302

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ / shares in Units, $ in Thousands				6 Months Ended
	Jul. 25, 2024 USD ($) shares	Jul. 22, 2024 USD ($) $ / shares shares	Jul. 12, 2024	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Subsequent Event [Line Items]
Payment of stock issuance costs \| $				$ 1,560
Subsequent event [Member]
Subsequent Event [Line Items]
Proceeds from initial public offer \| $		$ 161,900
Temporary equity converted into equity shares		6,160,385
Subsequent event [Member] \| Redeemable convertible preferred stock [Member]
Subsequent Event [Line Items]
Temporary equity stock split			0.2057
Subsequent event [Member] \| 2024 equity incentive plan [Member]
Subsequent Event [Line Items]
Share based compensation by share based award number of shares authorized for issuance		4,572,025
Subsequent event [Member] \| 2024 equity incentive plan [Member] \| New shares of common stock [Member]
Subsequent Event [Line Items]
Share based compensation by share based award number of shares authorized for issuance		2,630,000
Subsequent event [Member] \| 2024 equity incentive plan [Member] \| Shares available for issuance under the two thousand and twenty plan [Member]
Subsequent Event [Line Items]
Share based compensation by share based award number of shares authorized for issuance		115,436
Subsequent event [Member] \| 2024 equity incentive plan [Member] \| Common stock subject to outstanding awards granted [Member]
Subsequent Event [Line Items]
Share based compensation by share based award number of shares authorized for issuance		1,826,589
Subsequent event [Member] \| 2024 employee stock purchase plan [Member]
Subsequent Event [Line Items]
Share based compensation by share based award number of shares authorized for issuance		212,000
Subsequent event [Member] \| Simple agreement for future equity [Member]
Subsequent Event [Line Items]
Option indexed to issuers equity converted into common stock shares		2,391,418
Subsequent event [Member] \| IPO [Member]
Subsequent Event [Line Items]
Stock issued during the period shares new issues		13,920,000
Sale of stock issue price per share \| $ / shares		$ 12
Proceeds from initial public offer \| $		$ 167,000
Payment of stock issuance costs \| $		16,300
Sale of stock net consideration received on the transaction \| $		$ 150,700
Subsequent event [Member] \| Over-allotment option [Member]
Subsequent Event [Line Items]
Stock issued during the period shares new issues	1,000,000
Common stock shares subscribed but not issued		2,088,000
Proceeds from issuance of common stock \| $	$ 11,200
Subsequent event [Member] \| Common stock [Member]
Subsequent Event [Line Items]
Stockholders equity stock split			0.2057